Paeoniflorin and NAFLD: A Systematic Review and Meta-Analysis of Animal Studies With Mechanistic Insights.

Authors

Dachuan Jin, Shunqin Jin, Tao Zhou, Guoping Sheng, Mingfei Yao, Peng Gao, Guangming Li, Chuan Qin

Published in

Food science & nutrition. Volume 14. Issue 8. Pages e72192. Epub Aug 03, 2026.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major metabolic liver disorder with limited pharmacological options. Paeoniflorin (PF), a bioactive compound from Paeonia lactiflora, has shown hepatometabolic effects in experimental studies, but its overall efficacy in NAFLD models remains unclear. We searched PubMed, Embase, Web of Science, the Cochrane Library, CNKI, Wanfang, VIP, and CBM from inception to January 2026 for controlled animal studies evaluating PF in diet-induced NAFLD models. Two reviewers independently performed study selection, data extraction, and risk-of-bias assessment using SYRCLE's tool. Weighted mean differences or standardized mean differences with 95% confidence intervals were pooled using random-effects models. Ten studies were included, all using diet-induced models. PF treatment was associated with improvements in lipid metabolism, liver injury, glucose homeostasis, inflammation, and oxidative stress, including reductions in total cholesterol, triglycerides, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, body weight, fasting blood glucose, insulin resistance indices, tumor necrosis factor-α, and malondialdehyde, together with increased superoxide dismutase activity. High-density lipoprotein cholesterol showed no consistent improvement. Mechanistic findings suggested that PF may activate AMP-activated protein kinase, inhibit sterol regulatory element-binding protein-1c/fatty acid synthase-mediated lipogenesis, and modulate inflammatory and oxidative-stress pathways. However, substantial heterogeneity and incomplete reporting of randomization, allocation concealment, and blinding limited confidence in the evidence. PF showed promising preclinical effects in NAFLD, but further well-designed animal studies and clinical investigations are needed to clarify dose-response relationships, safety, and translational relevance.

PMID:
42548999
Bibliographic data and abstract were imported from PubMed on 04 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.